BioCorRx Inc. (BICX)
OTCMKTS · Delayed Price · Currency is USD
0.3510
-0.0280 (-7.39%)
At close: May 29, 2026
BioCorRx Revenue
BioCorRx had revenue of $214.54K in the quarter ending March 31, 2026, with 59.04% growth. This brings the company's revenue in the last twelve months to $876.88K, up 531.11% year-over-year. In the year 2025, BioCorRx had annual revenue of $797.24K with 10,301.10% growth.
Revenue (ttm)
876.88K
Revenue Growth
+531.11%
P/S Ratio
11.63
Revenue / Employee
292.29K
Employees
3
Market Cap
10.20M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 797.24K | 789.58K | 10,301.10% |
| Dec 31, 2024 | 7.67K | -81.50K | -91.40% |
| Dec 31, 2023 | 89.16K | -124.68K | -58.31% |
| Dec 31, 2022 | 213.84K | 165.57K | 342.99% |
| Dec 31, 2021 | 48.27K | -74.35K | -60.63% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veltex | 70.13M |
| Regional Health Properties | 66.23M |
| Selectis Health | 38.24M |
| Cardiff Lexington | 10.84M |
| Syra Health | 7.64M |
| Numinus Wellness | 4.71M |
| Stem Cell Authority | 3.33M |
| Xcelerate | 2.70M |
BioCorRx News
- 6 months ago - BioCorRx Inc. to Present at the Life Sciences Virtual Investor Forum December 11th - GlobeNewsWire
- 6 months ago - Diamond Equity Research Releases Update Note on BioCorRx®, Inc. (OTCQB: BICX) - GlobeNewsWire
- 9 months ago - Diamond Equity Research Initiates Coverage on BioCorRx®, Inc. (OTCQB: BICX) - GlobeNewsWire
- 1 year ago - BioCorRx Reports Business Update for the Second Quarter of 2024 - GlobeNewsWire
- 2 years ago - BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia - GlobeNewsWire
- 2 years ago - BioCorRx Reports Business Update for 2023 - GlobeNewsWire
- 2 years ago - BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD - GlobeNewsWire
- 2 years ago - BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors - GlobeNewsWire